Unbiased analysis of senescence associated secretory phenotype (SASP) to identify common components following different genotoxic stresses

Aging

Volumn 8, Issue 7, 2016, Pages 1316-1329

  Özcan, Servet ^a   Alessio, Nicola ^c   Acar, Mustafa B ^a   Mert, Eda ^a   Omerli, Fatih ^a   Peluso, Gianfranco ^d   Galderisi, Umberto ^a,b,c  

^a ERCIYES UNIVERSITY   (Turkey)

^b TEMPLE UNIVERSITY   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CNR   (Italy)

Author keywords

Mesenchymal stem cells; Secretome; Senescence

Indexed keywords

ADIPOCYTE; BONE MARROW CELL; CELL AGING; CYTOLOGY; DNA DAMAGE; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; OXIDATION REDUCTION REACTION; PHENOTYPE; PHYSIOLOGY;

ADIPOCYTES; BONE MARROW CELLS; CELLULAR SENESCENCE; DNA DAMAGE; HUMANS; MESENCHYMAL STROMAL CELLS; OXIDATION-REDUCTION; PHENOTYPE;

EID: 85010651800     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100971     Document Type: Article

References (43)

1. Campisi J and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740.
2. van Deursen JM. The role of senescent cells in ageing. Nature. 2014; 509:439-446.
3. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY and Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS biology. 2008; 6:2853-2868.
4. Krtolica A, Parrinello S, Lockett S, Desprez PY and Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:12072-12077.
5. Liu D and Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer research. 2007; 67:3117-3126.
6. Velarde MC, Demaria M and Campisi J. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdisciplinary topics in gerontology. 2013; 38:17-27.
7. Ozcan S, Alessio N, Acar MB, Toprak G, Gonen ZB, Peluso G and Galderisi U. Myeloma cells can corrupt senescent mesenchymal stromal cells and impair their anti-tumor activity. Oncotarget. 2015; 6:39482-39492. doi: 10.18632/oncotarget.5430.
8. Galderisi U and Giordano A. The gap between the physiological and therapeutic roles of mesenchymal stem cells. Medicinal research reviews. 2014; 34:1100-1126.
9. Squillaro T, Peluso G and Galderisi U. Clinical Trials with Mesenchymal Stem Cells: An Update. Cell transplantation. 201; 25:829-848.
10. Ranganath SH, Levy O, Inamdar MS and Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell stem cell. 2012; 10:244-258.
11. Galderisi U, Helmbold H, Squillaro T, Alessio N, Komm N, Khadang B, Cipollaro M, Bohn W and Giordano A. In vitro senescence of rat mesenchymal stem cells is accompanied by downregulation of stemness-related and DNA damage repair genes. Stem Cells Dev. 2009; 18:1033-1042.
12. Debacq-Chainiaux F, Erusalimsky JD, Campisi J and Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nature protocols. 2009; 4:1798-1806.
13. Shevchenko A, Tomas H, Havlis J, Olsen JV and Mann M. Ingel digestion for mass spectrometric characterization of proteins and proteomes. Nature protocols. 2006; 1:2856-2860.
14. Strioga M, Viswanathan S, Darinskas A, Slaby O and Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012; 21:2724-2752.
15. Bessarabova M, Ishkin A, JeBailey L, Nikolskaya T and Nikolsky Y. Knowledge-based analysis of proteomics data. BMC Bioinformatics. 2012; 16:S13.
16. Wittkop T, TerAvest E, Evani US, Fleisch KM, Berman AE, Powell C, Shah NH and Mooney SD. STOP using just GO: a multiontology hypothesis generation tool for high throughput experimentation. BMC Bioinformatics. 2013; 14:53.
17. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY). 2012; 4:159-165. doi: 10.18632/aging.100443
18. Blagosklonny MV. Geroconversion: irreversible step to cellular senescence. Cell cycle. 2014; 13:3628-3635.
19. Gilca M, Stoian I, Atanasiu V and Virgolici B. The oxidative hypothesis of senescence. Journal of postgraduate medicine. 2007; 53:207-213.
20. Haines DD, Juhasz B and Tosaki A. Management of multicellular senescence and oxidative stress. Journal of cellular and molecular medicine. 2013; 17:936-957.
21. Capasso S, Alessio N, Squillaro T, Di Bernardo G, Melone MA, Cipollaro M, Peluso G and Galderisi U. Changes in autophagy, proteasome activity and metabolism to determine a specific signature for acute and chronic senescent mesenchymal stromal cells. Oncotarget. 2015; 6:39457-39468. doi: 10.18632/oncotarget.6277.
22. Iyer RP, Patterson NL, Fields GB and Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. American journal of physiology Heart and circulatory physiology. 2012; 303:H919-930.
23. Nissinen L and Kahari VM. Matrix metalloproteinases in inflammation. Biochimica et biophysica acta. 2014; 1840:2571-2580.
24. Sariahmetoglu M, Crawford BD, Leon H, Sawicka J, Li L, Ballermann BJ, Holmes C, Berthiaume LG, Holt A, Sawicki G and Schulz R. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB journal. 2007; 21:2486-2495.
25. Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth FX, Nagase H, Tschesche H and Maskos K. Insights into MMP-TIMP interactions. Annals of the New York Academy of Sciences. 1999; 878:73-91.
26. Fernandez-Patron C, Radomski MW and Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circulation research. 1999; 85:906-911.
27. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I and Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000; 289:1202-1206.
28. Schonbeck U, Mach F and Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. Journal of immunology. 1998; 161:3340-3346.
29. Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L and Stetler-Stevenson WG. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/betacatenin complex expression in A549 lung cancer cells. Oncotarget. 2013; 4:163-173. doi: 10.18632/oncotarget.801.
30. Lee SJ, Tsang PS, Diaz TM, Wei BY and Stetler-Stevenson WG. TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells. Laboratory investigation. 2010; 90:374-382.
31. Seo DW, Kim SH, Eom SH, Yoon HJ, Cho YR, Kim PH, Kim YK, Han JW, Diaz T, Wei BY and Stetler-Stevenson WG. TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvascular research. 2008; 76:145-151.
32. Stetler-Stevenson WG and Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. Trends in molecular medicine. 2005; 11:97-103.
33. Severino V, Alessio N, Farina A, Sandomenico A, Cipollaro M, Peluso G, Galderisi U and Chambery A. Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell death & disease. 2013; 4:e911.
34. Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST and Shiio Y. Plasminogen activator inhibitor 1-insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:12052-12057.
35. Kim KS, Kim MS, Seu YB, Chung HY, Kim JH and Kim JR. Regulation of replicative senescence by insulin-like growth factor-binding protein 3 in human umbilical vein endothelial cells. Aging cell. 2007; 6:535-545.
36. Eren M, Boe AE, Murphy SB, Place AT, Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GR, Mutlu GM, Miyata T and Vaughan DE. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:7090-7095.
37. Fisher AB. Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase A(2) activities. Antioxidants & redox signaling. 2011; 15:831-844.
38. Horna-Terron E, Pradilla-Dieste A, Sanchez-de-Diego C and Osada J. TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology. International journal of molecular sciences. 2014; 15:23501-23518.
39. Vasseur S, Afzal S, Tardivel-Lacombe J, Park DS, Iovanna JL and Mak TW. DJ-1/PARK7 is an important mediator of hypoxiainduced cellular responses. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:1111-1116.
40. Byun HO, Han NK, Lee HJ, Kim KB, Ko YG, Yoon G, Lee YS, Hong SI and Lee JS. Cathepsin D and eukaryotic translation elongation factor 1 as promising markers of cellular senescence. Cancer research. 2009; 69:4638-4647.
41. Berger W, Steiner E, Grusch M, Elbling L and Micksche M. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cellular and molecular life sciences. 2009; 66:43-61.
42. Pasillas MP, Shields S, Reilly R, Strnadel J, Behl C, Park R, Yates JR, 3rd, Klemke R, Gonias SL and Coppinger JA. Proteomic analysis reveals a role for Bcl2-associated athanogene 3 and major vault protein in resistance to apoptosis in senescent cells by regulating ERK1/2 activation. Molecular & cellular proteomics. 2015; 14:1-14.
43. Ryu SJ and Park SC. Targeting major vault protein in senescence-associated apoptosis resistance. Expert opinion on therapeutic targets. 2009; 13:479-484.